Get the Stockscreener App
121.76
1.43%
-1.77
After Hours:
121.85
0.09
+0.07%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $121.76, with a volume of 10.33M.
It is down -1.43% in the last 24 hours and down -4.02% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$123.53
Open:
$123.23
24h Volume:
10.33M
Relative Volume:
1.65
Market Cap:
$211.73B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.27
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-3.30%
1M Performance:
-4.02%
6M Performance:
-7.58%
1Y Performance:
+6.89%
1-Day Range:
$121.53
$123.49
1-Week Range:
$121.53
$126.61
52-Week Range:
$113.39
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott stock drops, ABT traders eye earnings after MLK Day shuts Wall Street - TechStock²
Abbott Laboratories: Who is the newcomer to Pōkeno? - BusinessDesk | NZ
Abbott Laboratories (ABT) positioned to benefit as healthcare sector enters recovery phase - MSN
Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors - Chartmill
Is Abbott Laboratories (ABT) Price Weakness Creating A Potential Opportunity Now? - Yahoo Finance
Abbott (ABT) Declines More Than Market: Some Information for Investors - Yahoo Finance Singapore
Options Corner: Abbott Laboratories Offer Economic Insulation Ahead Of Earnings - Benzinga
FDA confirms recalls for Abbott CGM sensors—new lawsuit alleges company concealed information - Cardiovascular Business
TorHoerman Law Announces $495 Million Jury Verdict in Case Involving Abbott Laboratories - ACCESS Newswire
1 Healthcare Stock to Consider Right Now and 2 We Find Risky - FinancialContent
Assessing Abbott Laboratories (ABT) Valuation After The CES 2026 Launch Of Libre Assist AI Tool - simplywall.st
Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage - AOL.com
Abbott reportedly looks to expand CGM manufacturing plant in Ireland - MassDevice
C-Reactive Protein Testing Market Is Going to Boom |• Abbott • Siemens Healthineers - openPR.com
Nordea Investment Management AB Buys 18,974 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Julia Letlow - MarketBeat
Abbott Laboratories (ABT) Expected to Announce Earnings on Thursday - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories Target of Unusually Large Options Trading (NYSE:ABT) - MarketBeat
Retirement Planning Group LLC Grows Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Holdings Cut by Exencial Wealth Advisors LLC - MarketBeat
The Bull Case For Abbott Laboratories (ABT) Could Change Following Libre Assist AI Launch In Diabetes Care - simplywall.st
Gov't Didn't Allege Formula Was Contaminated, Abbott Says - Law360
ABT.SW Abbott Laboratories (SIX) volume spike 13 Jan 2026: CHF100 key - Meyka
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $154 - 富途牛牛
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance
Abbott, AtaCor Collaborate on Extravascular Implantable Cardioverter Defibrillator - Diagnostic and Interventional Cardiology
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Declares Quarterly Dividend of $0.63 - MarketBeat
MGO One Seven LLC Acquires 18,412 Shares of Abbott Laboratories $ABT - MarketBeat
Extracorporeal Membrane Oxygenation Machine Market Size to Hit USD 725.99 Million by 2033, Growing at a CAGR of 4.91% - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) is favoured by institutional owners who hold 80% of the company - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Purchases 10,635 Shares of Abbott Laboratories $ABT - MarketBeat
CPC Advisors LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief - Chicago Tribune
Abbott Laboratories Stock: Quiet Grind Higher as Wall Street Warms to the Recovery Story - AD HOC NEWS
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Institutional Investors Show Confidence in Abbott’s Healthcare Strategy - AD HOC NEWS
Is the Market Bullish or Bearish on Abbott Laboratories? - Benzinga
Abbott (ABT) Gains Ground in Glucose Monitoring Market - GuruFocus
Abbott, AtaCor collab on extravascular ICDs - MassDevice
Abbott Laboratories (ABT) Investor Outlook: Exploring a 14.95% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Acquired by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery - GlobeNewswire Inc.
Tema Etfs LLC Raises Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA - MarketBeat
Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears - TechStock²
Abbott Laboratories $ABT Shares Sold by New York State Teachers Retirement System - MarketBeat
Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage - TechStock²
Parnassus Investments LLC Acquires New Shares in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
2.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):